Synthetic biology and parasite genomics: engineering parasite-resistant human microbiomes for sustainable disease prevention

Abstract

Background

Recent progress in parasite genomics has is enabled for greater understanding of genetic structure of parasites, including the species of Plasmodium, Leishmania, and Trypanosoma. Cutting-edge next-generation sequencing (NGS) techniques, such as high-throughput sequencing, has enabled the discovery of essential genes linked to the metabolic pathways, drug resistance, and life cycle adaptations. Advancements in the field of genomics have enabled the deep understanding of biological processes and evolutionary adaptations of parasites.

Results

Investigating the genomes in various parasite strains has enhanced our understanding of their evolutionary adaptations, enhancing our capacity to predict epidemics and develop therapies that effectively act against various parasitic strains. Synthetic biology has also proposed novel treatment approaches, including the gene therapies and bioengineered microbes, that shows potential in fighting or inhibiting parasite illnesses. Revolutionary genome-editing methods, such as CRISPR-Cas9, have enabled the accurate genetic alterations, expediting the progress of sophisticated medicinal therapies, that are specifically designed for parasite management and eradication.

Conclusion

Microbiome engineering, an emerging area, provides a novel opportunities for disease prevention by integrating the techniques such as transplanting faecal microbiota and genetically tailored bacteria to restore microbial equilibrium and decrease parasite populations. Nevertheless, the enduring stability of modified microbiomes, possible environmental hazards, and ethical concerns related to gene editing emphasise the necessity for stringent safety measures and monitoring by regulatory authorities. Using these technologies responsibly and ethically is crucial to guarantee the continuous therapeutic advancement.

Graphic abstract